factor

(redirected from lethal factor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia.
Related to lethal factor: Bacillus anthracis toxin

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
A small-molecule that can inhibit anthrax lethal factor and is cell-permeable can potentially provide significant protection against anthrax as prophylactic and acute therapy.
Cengent Therapeutics' ability to rapidly discover and develop inhibitors of anthrax lethal factor is yet one more demonstration of the power of the company's structure-based drug design technology platform called Genes to Leads(R).
A small molecule that can inhibit the action of anthrax lethal factor can potentially provide significant protection against anthrax for prophylaxis and acute therapy, SBI reports.
Structural Bioinformatics' (SBI's) ability to rapidly discover and develop an inhibitor of anthrax lethal factor is yet another example of the power of the company's structure-based drug design technology platform called Genes-to-Leads(R).
The $754,259 two-year grant is expected to allow SBI to develop a small-molecule nonpeptide inhibitor of anthrax lethal factor (ALF).
Patent and Trademark Office's notice of allowance of patent approval for SBI's anthrax lethal factor inhibitors was announced by SBI in March, 2002.
In infectious disease, we are primarily focused on targeting metalloproteases, of which the anthrax lethal factor is one significant example.